Innocrin Pharmaceuticals Company
Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer.
Technology:
Immunotherapy
Industry:
PharmTech
Headquarters:
Durham, North Carolina, United States
Founded Date:
2004
Employees Number:
11-50
Funding Status:
Late Stage Venture
Estimated Revenue:
$1M to $10M
Register and Claim Ownership